Executive Summary
Cardiovascular disease remains the leading cause of mortality worldwide, with myocardial infarction and stroke accounting for significant morbidity and healthcare costs. This white paper proposes incorporating C-Reactive Protein (CRP) and Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) testing into routine annual physical examinations as evidence-based biomarkers for enhanced cardiovascular risk assessment.
These inflammatory biomarkers provide critical information beyond traditional lipid panels and can identify at-risk individuals who might otherwise be missed by conventional screening methods. The integration of these tests into standard practice represents a paradigm shift toward proactive, prevention-focused cardiovascular care.